Why the study?
Does oral tacrolimus reduce the incidence of biopsy-proven acute rejection compared to cyclosporine in heart transplant recipients?
Does oral tacrolimus reduce the incidence of biopsy-proven acute rejection compared to cyclosporine in heart transplant recipients?
Tacrolimus-based immunosuppression provides superior prevention of acute rejection compared to cyclosporine in heart transplant recipients, though it is associated with a higher risk of new-onset diabetes.
Answers are grounded in this paper and cite their sources.
Tacrolimus reduces acute rejection versus cyclosporine after heart transplant; confirms superiority of tacrolimus-based regimens in this RCT.
We compared efficacy and safety of tacrolimus (Tac)-based vs. cyclosporine (CyA) microemulsion-based immunosuppression in combination with azathioprine (Aza) and corticosteroids in heart transplant recipients. During antibody induction, patients were randomized (1:1) to oral treatment with Tac or CyA. Episodes of acute rejection were assessed by protocol biopsies, which underwent local and blinded central evaluation. The full analysis set comprised 157 patients per group. Patient/graft survival was 92.9% for Tac and 89.8% for CyA at 18 months. The primary end point, incidence of first biopsy proven acute rejection (BPAR) of grade >/= 1B at month 6, was 54.0% for Tac vs. 66.4% for CyA (p = 0.029) according to central assessment. Also, incidence of first BPAR of grade >/= 3A at month 6 was significantly lower for Tac vs. CyA; 28.0% vs. 42.0%, respectively (p = 0.013). Significant differences (p < 0.05) emerged between groups for these clinically relevant adverse events: new-onset diabetes mellitus (20.3% vs. 10.5%); post-transplant arterial hypertension (65.6% vs. 77.7%); and dyslipidemia (28.7% vs. 40.1%) for Tac vs. CyA, respectively. Incidence and pattern of infections over 18 months were comparable between groups, as was renal function. Primary use of Tac during antibody induction resulted in superior prevention of acute rejection without an associated increase in infections.
No takes yet. Share an insight, caveat, or question.
Grimm et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: